ADX-324 not checked

ADARx Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Hereditary Angioedema (2 trials), HAE (2 trials), Hereditary Angioedema - Type 1 (2 trials), Hereditary Angioedema - Type 2 (2 trials), Hereditary Angioedema (HAE)
Main trialPhase 3
“This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.”In the company’s words, NCT06960213 on ClinicalTrials.gov
Other names
siRNA

Other drugs for Hereditary Angioedema

All 8 drugs for Hereditary Angioedema

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Nov 2027 STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Phase 3Recruiting 30 Jun 2030 Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Phase 1/2Active, not recruiting 31 Dec 2027 Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ADX-324

Following is part of Solo: you see every change to ADX-324 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in